RT Journal Article
SR Electronic
T1 Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.220645
DO 10.3899/jrheum.220645
A1 Imane Bardan
A1 Karen Minde  Fagerli
A1 Joe Sexton
A1 Tore K.  Kvien
A1 Gunnstein Bakland
A1 Pawel Mielnik
A1 Yi Hu
A1 Gunhild Lien
A1 Berit Flatø
A1 Øyvind Molberg
A1 Eirik Klami  Kristianslund
A1 Anna-Birgitte Aga
YR 2022
UL http://www.jrheum.org/content/early/2022/11/10/jrheum.220645.abstract
AB Objective Compare effectiveness of tumor necrosis factor inhibitors (TNFi) ± comedication and methotrexate monotherapy (MTX mono) between adult juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) patients. Methods Adult JIA and RA patients were identified from the NOR-DMARD register. Disease activity measurements at baseline, 3, 6 and 12 months were compared between JIA and RA patients starting (1) TNFi and (2) MTX monotherapy, using age- and gender-weighted analyses. We calculated differences between JIA and RA in mean changes in DAS28, CDAI and SDAI, among other disease activity measures. DAS28, CDAI, SDAI and ACR/EULAR remission rates at 3, 6 and 12 months, as well as 6- and 12-month LUNDEX-corrected rates, were calculated. Results We identified 478 JIA patients (TNFi/MTX mono N=358/120) and 4637 RA patients (N=2292/2345). JIA patients had lower baseline disease activity compared to RA patients across treatment groups. After baseline disease activity adjustment there were no significant differences in disease activity change from baseline to 3, 6 and 12-months follow-up between JIA and RA patients for either treatment group. 12- month remission rates were similar between groups based on DAS28 (TNFi: JIA 55.2%, RA 49.5%. MTX mono: JIA 45.3%, RA 41.2%) and ACR/EULAR remission criteria (TNF: JIA 20.4%, RA 20.0%. MTX mono: JIA 17.0%, RA 12.7%). Median drug survival (years) was similar for JIA and RA in both treatment groups (TNFi: JIA 1.2, RA 1.4; MTX mono: JIA 1.3, RA 1.6) Conclusion TNFi and MTX mono are effective in adult JIA, with similar effectiveness as in RA.